Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cryo Cell International (CCEL) EBITDA Margin (2016 - 2025)

Cryo Cell International (CCEL) has disclosed EBITDA Margin for 16 consecutive years, with 62.98% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 2543.0% to 62.98% in Q4 2025 year-over-year; TTM through Nov 2025 was 1.55%, a 340.0% decrease, with the full-year FY2025 number at 1.38%, down 242.0% from a year prior.
  • EBITDA Margin was 62.98% for Q4 2025 at Cryo Cell International, down from 24.29% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 27.69% in Q2 2021 to a low of 84.79% in Q4 2023.
  • A 5-year average of 1.61% and a median of 15.2% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -4715bps in 2023, then skyrocketed 4723bps in 2024.
  • Cryo Cell International's EBITDA Margin stood at 11.05% in 2021, then plummeted by -241bps to 37.64% in 2022, then plummeted by -125bps to 84.79% in 2023, then skyrocketed by 56bps to 37.56% in 2024, then tumbled by -68bps to 62.98% in 2025.
  • Per Business Quant, the three most recent readings for CCEL's EBITDA Margin are 62.98% (Q4 2025), 24.29% (Q3 2025), and 18.83% (Q2 2025).